The usefulness of adiponectin’s concentration’s measurement in the pediatric population Review article
Article Sidebar
Published:
Sep 30, 2011
Keywords:
adiponectin, pediatric population, metabolic disorders, marker
Main Article Content
Abstract
The aim of this paper is to concisely summarize the current state of knowledge about adiponectin: one of the most interesting adipocytokines, considering its multidirectional systemic activity. The authors present the usefulness of adiponectin as a marker of a range of metabolic processes and its role in monitoring of selected circulation’s pathophysiology’s mechanisms. The authors also review current research concerning adiponectin in the pediatric population in the context of both metabolic disorders and other diseases.
Article Details
How to Cite
Mirecka, M., & Karolczak, M. A. (2011). The usefulness of adiponectin’s concentration’s measurement in the pediatric population. Medycyna Faktow (J EBM), 4(3(12), 34-40. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2518
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Brochu-Gaudreau K., Rehfeldt C., Blouin R. et al.: Adiponectin action from head to toe. Endocr. 2010; 37: 11-32.
2. Scherer P.E., Williams S., Fogliano M. et al.: A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 1995; 270: 26746-9.
3. Hu E., Liang P., Spiegelman B.M.: AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 1996; 271: 10697-703.
4. Maeda K., Okubo K., Shimomura I. et al.: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (Adipose Most abundant gene transcript 1). Biochem. Biophys. Res. Commun. 1996; 221: 286-9.
5. Nakano Y., Tobe T., Choi-Miura N. et al.: Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J. Biochem. 1996; 120: 803-12.
6. Kissebah A.H., Sonnenberg G.E., Myklebust J. et al.: Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc. Natl. Acad. Sci. USA 2000; 97: 14478-83.
7. Shapiro L., Scherer P.E.: The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr. Biol. 1998; 8: 335-8.
8. Waki H., Yamauchi T., Kamon J. et al.: Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J. Biol. Chem. 2003; 278: 40352-40363.
9. Yamauchi T., Kamon J., Ito Y. et al.: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-9 (erratum 2004; 431: 1123).
10. Kharroubi I., Rasschaert J., Eizirik D.L. et al.: Expression of adiponectin receptors in pancreatic beta cells. Biochem. Biophys. Res. Commun. 2003; 312: 1118-1122.
11. Berner H.S., Lyngstadaas S.P., Spahr A. et al.: Adiponectin and its receptors are expressed in bone-forming cells. Bone 2004; 35: 842-849.
12. Hug C., Wang J., Ahmad N.S. et al.: T-cadherin is a receptor for hexameric and high-molecular forms of Acrp30/adiponectin. Proc. Natl. Acad. Sci. 2004; 101: 10308-10313.
13. Debard C., Laville M., Berbe V. et al.: Expression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of type 2 diabetic patients. Diabetologia 2004; 47: 917-25.
14. Yilmaz M.I., Sonmez A., Caglar K. et al.: Peroxisome proliferator-activated receptor gamma (PPAR gamma) agonist increases plasma adiponectin levels in type 2 diabetec patients with proteinuria. Endocrine 2004; 25: 207-214.
15. Owecki M.: Adiponektyna i paradoks adiponektyny w metabolizmie człowieka. Przegląd Kardiodiabetologiczny 2009; 4(1): 42-48.
16. Olszewski W.: Stężenie greliny i adiponektyny u pacjentów z cukrzycą typu 2 leczonych metforminą lub gliklazydem. Rozprawa doktorska 2010.
17. Qi Y., Takahashi N., Hileman S.M. et al.: Adiponectin acts in the brain to decrease body weight. Nat. Med. 2004; 10: 524-529.
18. Yamauchi T., Kamon J., Waki H. et al.: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001; 7: 941-6.
19. Baranowska B., Bik W.: Fizjologiczna rola adiponektyny. Postępy Nauk Medycznych 2010; 6: 503-508.
20. Diez J.J., Igiesias P.: The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur. J. Endocrinol. 2003; 148: 293-300.
21. Ouchi N., Ohishi M., Kihara S. et al.: Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42: 231-234.
22. Chen M.P., Tsai J.C., Chung F.M. et al.: Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 821-6.
23. Sakuta H., Suzuki T., Yasuda H., Ito T.: Adiponectin levels and cardiovascular risk factors in Japanese men with type 2 diabetes. Endocr. J. 2005; 52: 241-4.
24. Mather K.J., Funahashi T., Matsuzawa Y. et al.: Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 2008; 57: 980-986.
25. Seino Y., Hirose H., Saito I., Itoh H.: High-molecular-weight adiponectin is a predictor of progression to metabolic syndrome: a population-based 6-year follow-up study in Japanese men. Metabolism Clin. Exp. 2009; 58: 355-360.
26. Liang K.W., Lee W.J., Lee W.L. et al.: Decreased ratio of high-molecular-weight to total adiponectin is associated with angiographic coronary atherosclerosis severity but not restenosis. Clin. Chim. Act. 2009; 405: 114-118.
27. Pupek-Musialik D., Bogdański P.: Rola adiponektyny i czynnika martwicy nowotworów (TNF-alfa) w patogenezie nadciśnienia tętniczego związanego z otyłością. Postępy Nauk Medycznych 2004; 4: 12-19.
28. Bik W.: Ocena zależności wydzielania adipokin i insulinooporności oraz asocjacji wybranych polimorfizmów genów adiponektyny i rezystyny w otyłości. Postępy Nauk Medycznych 2009; 12: 912-980.
29. Chen H., Montagnani M., Funahashi T. et al.: Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem. 2003; 278: 45021-6.
30. Ohara T., Kim J., Asakura M. et al.: Plasma adiponectin is associated with plasma brain natriuretic peptide and cardiac function in healthy subjects. Hypertens. Res. 2008; 31: 825-31.
31. Tsutamoto T., Tanaka T., Sakai H. et al.: Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur. Heart J. 2007; 28: 1723-1730.
32. Yamamoto Y., Hirose H., Saito I. et al.: Correlation of the adipocyte-derived protein adiponectin resistance index and serum high density lipoprotein - cholesterol, independent of body mass index, in the Japanese population. Clin. Sci. (Lond.) 2002; 103(2): 137-142.
33. Głowińska-Olszewska B., Urban M., Koput A.: Adipocytokiny i markery zapalenia w zespole metabolicznym u młodzieży. Endokrynologia Pediatryczna 2008; 7: 23.
34. Kowalska I., Straczkowski M., Nikolajuk A. et al.: Plasma adiponectin concentration and tumor necrosis factor-alpha system activity in lean nondiabetic offspring of type 2 diabetic subjects; Eur. J. Endocrinol. 2006; 154: 319-24.
35. Valle M., Martos R., Gascon F. et al.: Low-grade systemic inflammation, hypoadiponectinemia and a high concentration of leptin are present in very young obese children, and correlate with metabolic syndrome. Diabetes Metab. 2005; 31: 55-62.
36. Reinehr T., Roth C., Menke T. et al.: Adiponectin before and after weight loss in obese children. J. Clin. Endocrinol. Metab. 2004; 89: 3790-4.
37. Liu Y.L., Liang H.R., Liu H.T. et al.: Association of serum adiponectin levels with artherosclerosis and the metabolic syndrome in obese children. J. Pediatr. Endocrinol. Metab. 2010; 8: 743-51.
38. Chrzanowska J., Zubkiewicz-Kucharska A., Noczyńska A.: Ocena zależności między wybranymi adipocytokinami a obecnością zaburzeń metabolicznych u otyłych nastolatków – badania wstępne. Nadciśnienie Tętnicze 2008; 12: 94-100.
2. Scherer P.E., Williams S., Fogliano M. et al.: A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 1995; 270: 26746-9.
3. Hu E., Liang P., Spiegelman B.M.: AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 1996; 271: 10697-703.
4. Maeda K., Okubo K., Shimomura I. et al.: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (Adipose Most abundant gene transcript 1). Biochem. Biophys. Res. Commun. 1996; 221: 286-9.
5. Nakano Y., Tobe T., Choi-Miura N. et al.: Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J. Biochem. 1996; 120: 803-12.
6. Kissebah A.H., Sonnenberg G.E., Myklebust J. et al.: Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc. Natl. Acad. Sci. USA 2000; 97: 14478-83.
7. Shapiro L., Scherer P.E.: The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr. Biol. 1998; 8: 335-8.
8. Waki H., Yamauchi T., Kamon J. et al.: Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J. Biol. Chem. 2003; 278: 40352-40363.
9. Yamauchi T., Kamon J., Ito Y. et al.: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-9 (erratum 2004; 431: 1123).
10. Kharroubi I., Rasschaert J., Eizirik D.L. et al.: Expression of adiponectin receptors in pancreatic beta cells. Biochem. Biophys. Res. Commun. 2003; 312: 1118-1122.
11. Berner H.S., Lyngstadaas S.P., Spahr A. et al.: Adiponectin and its receptors are expressed in bone-forming cells. Bone 2004; 35: 842-849.
12. Hug C., Wang J., Ahmad N.S. et al.: T-cadherin is a receptor for hexameric and high-molecular forms of Acrp30/adiponectin. Proc. Natl. Acad. Sci. 2004; 101: 10308-10313.
13. Debard C., Laville M., Berbe V. et al.: Expression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of type 2 diabetic patients. Diabetologia 2004; 47: 917-25.
14. Yilmaz M.I., Sonmez A., Caglar K. et al.: Peroxisome proliferator-activated receptor gamma (PPAR gamma) agonist increases plasma adiponectin levels in type 2 diabetec patients with proteinuria. Endocrine 2004; 25: 207-214.
15. Owecki M.: Adiponektyna i paradoks adiponektyny w metabolizmie człowieka. Przegląd Kardiodiabetologiczny 2009; 4(1): 42-48.
16. Olszewski W.: Stężenie greliny i adiponektyny u pacjentów z cukrzycą typu 2 leczonych metforminą lub gliklazydem. Rozprawa doktorska 2010.
17. Qi Y., Takahashi N., Hileman S.M. et al.: Adiponectin acts in the brain to decrease body weight. Nat. Med. 2004; 10: 524-529.
18. Yamauchi T., Kamon J., Waki H. et al.: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001; 7: 941-6.
19. Baranowska B., Bik W.: Fizjologiczna rola adiponektyny. Postępy Nauk Medycznych 2010; 6: 503-508.
20. Diez J.J., Igiesias P.: The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur. J. Endocrinol. 2003; 148: 293-300.
21. Ouchi N., Ohishi M., Kihara S. et al.: Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42: 231-234.
22. Chen M.P., Tsai J.C., Chung F.M. et al.: Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 821-6.
23. Sakuta H., Suzuki T., Yasuda H., Ito T.: Adiponectin levels and cardiovascular risk factors in Japanese men with type 2 diabetes. Endocr. J. 2005; 52: 241-4.
24. Mather K.J., Funahashi T., Matsuzawa Y. et al.: Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 2008; 57: 980-986.
25. Seino Y., Hirose H., Saito I., Itoh H.: High-molecular-weight adiponectin is a predictor of progression to metabolic syndrome: a population-based 6-year follow-up study in Japanese men. Metabolism Clin. Exp. 2009; 58: 355-360.
26. Liang K.W., Lee W.J., Lee W.L. et al.: Decreased ratio of high-molecular-weight to total adiponectin is associated with angiographic coronary atherosclerosis severity but not restenosis. Clin. Chim. Act. 2009; 405: 114-118.
27. Pupek-Musialik D., Bogdański P.: Rola adiponektyny i czynnika martwicy nowotworów (TNF-alfa) w patogenezie nadciśnienia tętniczego związanego z otyłością. Postępy Nauk Medycznych 2004; 4: 12-19.
28. Bik W.: Ocena zależności wydzielania adipokin i insulinooporności oraz asocjacji wybranych polimorfizmów genów adiponektyny i rezystyny w otyłości. Postępy Nauk Medycznych 2009; 12: 912-980.
29. Chen H., Montagnani M., Funahashi T. et al.: Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem. 2003; 278: 45021-6.
30. Ohara T., Kim J., Asakura M. et al.: Plasma adiponectin is associated with plasma brain natriuretic peptide and cardiac function in healthy subjects. Hypertens. Res. 2008; 31: 825-31.
31. Tsutamoto T., Tanaka T., Sakai H. et al.: Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur. Heart J. 2007; 28: 1723-1730.
32. Yamamoto Y., Hirose H., Saito I. et al.: Correlation of the adipocyte-derived protein adiponectin resistance index and serum high density lipoprotein - cholesterol, independent of body mass index, in the Japanese population. Clin. Sci. (Lond.) 2002; 103(2): 137-142.
33. Głowińska-Olszewska B., Urban M., Koput A.: Adipocytokiny i markery zapalenia w zespole metabolicznym u młodzieży. Endokrynologia Pediatryczna 2008; 7: 23.
34. Kowalska I., Straczkowski M., Nikolajuk A. et al.: Plasma adiponectin concentration and tumor necrosis factor-alpha system activity in lean nondiabetic offspring of type 2 diabetic subjects; Eur. J. Endocrinol. 2006; 154: 319-24.
35. Valle M., Martos R., Gascon F. et al.: Low-grade systemic inflammation, hypoadiponectinemia and a high concentration of leptin are present in very young obese children, and correlate with metabolic syndrome. Diabetes Metab. 2005; 31: 55-62.
36. Reinehr T., Roth C., Menke T. et al.: Adiponectin before and after weight loss in obese children. J. Clin. Endocrinol. Metab. 2004; 89: 3790-4.
37. Liu Y.L., Liang H.R., Liu H.T. et al.: Association of serum adiponectin levels with artherosclerosis and the metabolic syndrome in obese children. J. Pediatr. Endocrinol. Metab. 2010; 8: 743-51.
38. Chrzanowska J., Zubkiewicz-Kucharska A., Noczyńska A.: Ocena zależności między wybranymi adipocytokinami a obecnością zaburzeń metabolicznych u otyłych nastolatków – badania wstępne. Nadciśnienie Tętnicze 2008; 12: 94-100.